New cell therapy cocktail takes on tough lymphoma

NCT ID NCT07125872

Recruiting now Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 31, 2026 · Last updated May 01, 2026 · Updated 2 times

Summary

This study tests a new combination of treatments for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The approach uses specially engineered immune cells (CD19 t-haNK) plus an immune booster (N-803) along with the standard drug rituximab. The goal is to see how many participants' tumors shrink or disappear, and to monitor side effects. About 20 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED B-CELL NON HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Albert Cellular Therapy
RECRUITING

Pretoria, 0044, South Africa

Contact

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Dr. Jackie Thomson Inc
RECRUITING

Johannesburg, 2193, South Africa

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSED B-CELL NON HODGKIN LYMPHOMA RELAPSED B-CELL NON HODGKIN LYMPHOMA